comparemela.com

Latest Breaking News On - Mankind pharma ipo subscription - Page 3 : comparemela.com

Mankind Pharma IPO subscribed 21% on day 2 so far

A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis but some analysts have raised red flags over rich valuations and the complete OFS nature.

Mankind Pharma IPO subscribed 2% during initial two-hour bidding process on Day 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.